IJMHS slider images

Clinical Efficacy of Concurrent Therapy with Oral FDC Tablet of Euphorbia Prostrataplus Calcium Dobesilate and Topical FDC Cream of Euphorbia Prostrataplus Lidocaine in the Management of Haemorrhoids: A Prospective, Open-Labeled Multicentric Study

Authors: KunalJ. Khobragade, C.S.Patil, Nilesh E. Borkar
Abstract:Objective:Haemorrhoids are associated with bleeding, pain, itching, exudation and swelling. So there is an unmet need for effective treatment by both oral and topical drugs. Hence this study was designed to evaluate the efficacy of oral Euphorbia Prostratafortified with Calcium Dobesilate and topical cream of Euphorbia Prostratawith Lidocaine.Methods: The study was a prospective, open label, single arm, multicentric study, in 30 patients with hemorrhoids treated with oral FDC Euphorbia Prostrataextract 100 mg plus Calcium Dobesilate 500 mg and topical FDC cream of Euphorbia Prostrata extract 1% w/w plus Lidocaine 3% w/w for 14 days.Symptoms like bleeding, pain, itching, exudation and swelling were assessed and scored during and at the end of the study.Results: There was decline from the baseline value scores right from day 4 i.e. bleeding (0.97±0.15), pain (0.60±0.13), itching (0.47±0.13), exudation (0.13±0.06) and swelling (0.43±0.09); after 7 days bleeding (0.15±0.07), pain (0.12±0.06), itching (0.15±0.07), exudation (0.15±0.07) and swelling (0.19±0.08) and after day 14 the symptoms of bleeding (0.09±0.06), pain (0.08±0.06) and swelling (0.08±0.06) were almost cured while symptoms like itching (0.00±0.00), exudation (0.00±0.00) disappeared completely. There was reduction in the number of patient’s population with symptoms towards the end of the study.Conclusion: Oral Euphorbia Prostrataextract 100 mg fortified with Calcium Dobesilate 500 mg and topical cream of Euphorbia Prostrataextract 1% w/w with Lidocaine 3% w/w showed maximum improvement during first 4 days of therapy and achieved total improvement till the end of therapy thus providing multimodal targeted approach to treat a multimodal haemorrhoidal disease.
Year: 2019
Month: October
Volume: 8
Issue: 4
Published on: 24-10-2019